BEGIN:VCALENDAR
VERSION:2.0
PRODID:Linklings LLC
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-LIC-LOCATION:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20241017T183511Z
LOCATION:Harbor Ballroom A
DTSTART;TZID=America/Los_Angeles:20241015T150500
DTEND;TZID=America/Los_Angeles:20241015T152500
UID:ncs_NCS 2024_sess108_ccrnt265@linklings.com
SUMMARY:Precision Pediatric Neurocritical Care: Genetic Diagnoses and Quan
 titative EEG for Tailored Therapies"
DESCRIPTION:Breakout Session\n\nCraig Press (Children's Hospital of Philad
 elphia)\n\nIn the rapidly evolving field of pediatric neurocritical care, 
 the integration of genetic diagnoses and quantitative EEG (qEEG) is paving
  the way for precision medicine. We will explore the latest advancements u
 sing case vignettes to highlight how rapid or known genetic testing allows
  for a more accurate diagnosis and prognosis and tailored therapies contri
 buting to improved outcomes. Concurrently, we will examine how qEEG can be
  used to both monitor and measure cerebral function but also identify tren
 ds in seizure responsiveness that otherwise are difficult to identify. \n\
 nOur discussion will begin with an examination of gain-of-function sodium 
 channelopathies (SCN2A & SCN8A), which are some of the most common cause o
 f early genetic epilepsies and can be targeted with sodium channel drugs. 
   Cases presented will highlight how early diagnosis can improve seizure c
 ontrol with aggressive dosing regimens targeting high or "supra" therapeut
 ic levels. \n\nNext, the session will cover the role of qEEG in monitoring
  the efficacy of seizure therapies. Attendees will learn how real-time bra
 in activity data can inform adjustments to treatment plans, ensuring that 
 each child receives the most effective therapy based on their unique neuro
 physiological responses. \n\nFinally, we will delve into the prognostic va
 lue of qEEG following cardiac arrest in children. New data continues stren
 gthen the link between qEEG features (e.g., suppression ratio, and relativ
 e beta, alpha and delta activity) and the likelihood of neurological recov
 ery.  These features many help families make informed decisions about care
  and allow bedside providers to trend novel neuroprotective biomarkers.\n\
 nTrack: Clinical Practice\n\nFocus Area: Coma, Multimodal Neuromonitoring 
 (invasive/non-invasive), Pediatric, Provider Education Topics (eg fellowsh
 ip training, competency assessment, etc), Status Epilepticus\n\nTarget Aud
 ience: Intermediate\n\nSession Chair: Mark Wainwright (University of Washi
 ngton, Seattle Childrens Hospital)
END:VEVENT
END:VCALENDAR